+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06246916

Comparing Fixed-Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab for Advanced or Metastatic Melanoma

Led by Regeneron Pharmaceuticals · Updated on 2026-10-26

560

Participants Needed

113

Research Sites

328 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an experimental drug combination of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab in adults with unresectable or metastatic melanoma, a serious skin cancer. The study aims to assess the safety and effectiveness of these treatments, including side effects and how the body responds to the drugs. It is a phase 3 clinical trial designed to compare these regimens directly. Participants receive intravenous doses of either fianlimab plus cemiplimab every 3 weeks or relatlimab plus nivolumab every 4 weeks. The study randomly assigns patients to one of these two treatment groups. Treatment continues while monitoring for response and side effects, with the study lasting up to 72 months for assessing outcomes. During the trial, participants undergo regular evaluations including scans to measure tumor response, blood tests to monitor drug levels and antibodies against the drugs, and assessments of side effects. Researchers collect data on overall survival, disease control, and safety throughout the study period. Follow-up and monitoring may continue for several years to fully understand the treatments impacts.

CONDITIONS

Brief Title

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here